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Purpose: To investigate the safety and inhibitory effects of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine
(HDP-PMEG) on ocular cell proliferation and collagen matrix contraction.
Methods: For the antiproliferation studies, various ocular cell monolayers were exposed to HDP-PMEG, PMEG, 5-
fluorouracil (5-FU), and daunorubicin (DNB). For the collagen contraction studies, retinal pigment epithelium (RPE) cells
seeded onto type I collagen lattices were exposed for a single 5- or 50-min period to various concentrations of HDP-PMEG
or 5-FU. For the cytotoxicity study, trypan blue exclusion tests were performed using a human Müller cell line. Cytotoxicity
was determined up to 4 days after treatment.
Results: The proliferation of RPE cells, scleral fibroblasts, vessel endothelial cells, and ocular melanoma cells can all be
significantly inhibited by HDP-PMEG. Its inhibitory effects on those cells were uniformly stronger than that of 5-FU.
Contraction of the collagen matrix containing RPE cells was significantly inhibited by HDP-PMEG and by 5-FU at
concentrations of 20 µM and 2,000 µM, respectively, as compared with controls (p<0.05). The safety profile of HDP-
PMEG was significantly better than 5-FU and daunorubicin. The ocular therapeutic index is 1,100 for HDP-PMEG, 17.2
for 5-FU, and 1.25 for daunorubicin.
Conclusions: HDP-PMEG possesses a significant inhibitory effect on the proliferation of RPE, retinal glial cells, scleral
fibroblasts, and ocular melanoma cells. HDP-PMEG is also genotoxic and may be used as a single short application for
the modulation of unwanted ocular proliferation.
Unwanted ocular proliferation consists of an array of
diseases such as proliferative vitreoretinopathy (PVR) and
retinal surface proliferation including epiretinal membrane
(ERM) and macular pucker. Their pathophysiology involves
many aspects of cell biology and studies have suggested that
retinal pigment epithelial (RPE) cells and glial cells are the
major  cell  components  of  retina  proliferation  [1,2].  In
addition,  pathological  angiogenesis  and  abnormal  vessel
growth are involved with these scarring processes [3]. These
diseases share a common feature in which the participating
cells lose their quiescent nature and trans-differentiate to fast
proliferating cells. Inhibition of the proliferation of those cells
has been investigated, including the use of the FDA-approved
antiproliferative drugs daunorubicin [4] and 5-flourouracil
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[5]. However, no ideal compound or formulation has been
identified  for  effective  clinical  treatment  because  of  the
potential toxicity or the insufficient evidence for efficacy [4,
5].
Acyclic nucleoside phosphonates (ANPs) are nucleotide
analogs  with  significant  antiviral,  cytostatic  and
antiproliferative  activities  [6].  Three  ANPs  (cidofovir,
adefovir, and tenofovir) are FDA-approved as antivirals [7].
Among ANPs with inhibitory effects toward dividing cells, 9-
[2-(phosphonomethoxy)ethyl] guanine (PMEG, Figure 1) is
one of the most potent [8], the genotoxicity of PMEG being
comparable to that of mitomycin C [9], an inhibitor of DNA
synthesis which is administered as a single short exposure
during anti-glaucoma filtering surgery to prevent fibroblast
proliferation at the surgical site [10]. In proliferating cells,
PMEG is metabolized to PMEG diphosphate (PMEGpp), a
potent inhibitor of replicative human polymerases α, δ, and
ε,  resulting  in  cytotoxicity  [8].  PMEG  is  active  against
leukemia and melanoma in animal tumor models [11], and
prodrug derivatives related to PMEG have been synthesized
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627that are effective against lymphoma in dogs [12]. Due to its
potent antiproliferative effects, we felt that PMEG may also
be a good candidate for local treatment of ocular proliferative
diseases. However, the utility of intravitreally administered
PMEG is limited by its short intravitreal residence time and
toxicity,  especially  ocular  hypotony  [13].  Therefore,
successful  intravitreal  application  of  PMEG  and  other
antiproliferative ANPs may depend on the development of
new  derivatives  with  reduced  toxicity,  enhanced
pharmacokinetic properties (i.e., sustained release), and the
potential  to  selectively  deliver  high  concentrations  of  the
active diphosphate to ocular tissues.
To achieve this objective, we focused on the previously
reported  lipophilic  PMEG  prodrug,  hexadecyloxypropyl-
PMEG (HDP-PMEG, Figure 1) [14]. Earlier studies have
shown that the antiviral activity of PMEG and other ANPs can
be greatly increased by esterification with alkoxyalkyl groups
such as hexadecyloxypropyl (HDP) due to increased cell entry
of  the  lipid-modified  drug  leading  to  higher  intracellular
levels of the active diphosphate metabolite [15]. In addition,
we showed previously that alkoxyalkyl modified ANPs and
nucleoside monophosphates are sparingly soluble in vitreous,
and as a result, are slowly released from an intravitreal depot
to produce a sustained release effect [16,17]. This study was
designed to evaluate the potential of HDP-PMEG for local,
slow-release  therapy  of  PVR,  single  infusion  during  a
vitrectomy, or as a short contact application for preventing
excessive fibrosis following anti-glaucoma filtering surgery.
To this end, we examined the in vitro antiproliferative activity
of HDP-PMEG against six human cell lines, including cell
components involved in vitreoretinal proliferation and ocular
melanoma. To gain additional evidence of antiproliferative
activity, we also assessed the ability of HDP-PMEG to prevent
collagen matrix contraction.
METHODS
Antiproliferative activity assay and cytotoxicity study: HDP-
PMEG was synthesized as previously described [14]. The
current study was undertaken to test the possibility of an
ocular  application  of  HDP-PMEG  to  treat  unwanted
intraocular proliferation as well as ocular neoplasm which
also  involves  fast  cell  proliferation.  The  antiproliferation
activity of HDP-PMEG was tested on six human cell lines:
two human retinal cell lines, including pigment epithelium
ARPE19  (CRL-2302;  ATCC,  Manassas,  VA)  and  Müller
cells  (MIO-M1,  a  gift  of  Dr.  Gloria  Astrid  Limb,  Ocular
Repair and Regeneration Biology Unit, Departments of Cell
Biology and Pathology, Institute of Ophthalmology, London,
UK) [18]; a human endothelial-like immortalized cell line
EA-HY926, derived from the fusion of human umbilical vein
endothelial cells (HUVEC) with the lung carcinoma cell line
A549 (CRL-2922; ATCC); and three ocular uveal melanoma
cell lines, including OCM1 [19], M23 (established in the New
York Eye and Ear Infirmary, New York, NY) [20] and SP6.5
(kind  gift  from  Dr.  Guy  Pelletier,  Research  Center  of
Immunology, Quebec, Canada) [21]. The first three cell types
are  the  major  cell  components  involving  vitreoretinal
proliferation;  the  last  three  cell  types  represent  ocular
melanoma.
ARPE19 cells were cultured in DMEM/Ham’s F12 (1:1;
Gibco, Invitrogen, Paisley, UK) supplemented with 10% FBS
(Gibco, Invitrogen) and OCM1 cells were cultured in Nutrient
Mixture  Ham’s  1640  RPMI  medium  (Gibco,  Invitrogen)
supplemented with 10% FBS. M23, SP6.5, EA.HY926 and
Müller  cells  (MIO-M1)  were  cultured  in  DMEM  (Gibco,
Invitrogen) containing 10% FBS. The parallel studies were
performed  using  PMEG  and  the  other  two  well  known
antiproliferation  agents,  5-fluorouracil  (5-FU;  Sigma,  St.
Louis, MO) and daunorubicin (DNB; Sigma). Stock solutions
of HDP-PMEG and PMEG were made in DMSO (Sigma) and
stock solutions of 5-FU and daunorubicin were made in PBS.
All testing concentrations were diluted from the stock solution
using cell culture medium supplemented with 2% FBS. The
final highest concentration of DMSO was 0.08% which was
confirmed not toxic to the cells used in the current study in a
separate study (data not shown). Cells cultured without the
drug were used as controls. Final concentrations of the testing
compounds were 20 μM, 10 μM, 1 μM, 0.1 μM, 0.01 μM and
0.001 μM; 20 µM was the highest possible concentration
tested  for  HDP-PMEG  due  to  its  poor  solubility,  though
50 μM and 100 μM concentrations were also tested for the
other compounds. The cells were seeded into a 96 well plate
with 5,000 cells per well and were incubated at 37 °C in 5%
carbon dioxide which will reach near 100% confluence in
Figure 1. Chemical structure of PMEG and HDP-PMEG.
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628control wells within the projected 4-day culture. After 4 days,
the cultured cells will manifest a contact inhibition effect,
which  could  potentially  confound  the  results  of  the
proliferation study, so day 4 was used as the study end point.
After 4 days of incubation with 200 µl test solution, cell
viability  was  measured  using  Promega  MTS  (Promega
Corporation, Madison, WI) assay in which the conversion of
MTS  into  aqueous,  soluble  formazan  is  accomplished  by
dehydrogenase enzymes found in metabolically active cells.
The quantity of formazan product as measured by the amount
of 490nm absorbance is directly proportional to the number
of living cells in culture. The study was repeated three times
and five replicates were used within each study.
For  the  cytotoxicity  study,  trypan  blue  dye  (Sigma)
exclusion tests were performed using the Müller cell line,
which  originated  from  human  retina  and  has  a  slower
replication than ARPE19 or the other cells used in this study,
to  better  represent  quiescent  retina  cells.  The  Müller  cell
culture and drug exposure was the same as described in the
above MTS assay. The trypan blue staining in the 96-well
plate was evaluated after a 4-day exposure to HDP-PMEG, 5-
FU, Daunorubicin, or 2% DMEM (control). Five images from
5 different locations in each well were acquired immediately
after removing the dye. The total cell count and the trypan blue
positive cell count for each well were calculated from the
images and expressed as a percentage.
Antiproliferation study after a single, short-term exposure:
Fifty micro liters of either the ARPE19, or Müller cell, or
anterior scleral fibroblast [22] suspension (2,000 cells) was
added into each well of a 96-well plate. After the cells were
well  adhered  to  the  plate’s  bottom,  the  cells  were  then
exposed, in sextuplicate, to 200 μl/well of HDP-PMEG, 5-FU,
or serum-free DMEM/F12 medium (control) for a period of 5
or 50 min. The 5-min exposure was used as an intended
implication for intraoperative use for anti-glaucoma filtering
surgery  and  a  50-min  contact  was  used  as  an  intended
implication for infusion during a vitrectomy for PVR. The
concentrations used were 20 μM, 6.32 μM, and 2 μM for HDP-
PMEG and 20 mM, 6.32 mM, 2 mM, 200 μM, and 20 μM for
5-FU (sigma). After an exposure of 5 or 50 min, the solution
containing the test drug was removed and 200 μl fresh culture
medium was added back into each well. The cultures were
incubated at 37 °C in 5% carbon dioxide for 7 days with the
culture medium changed once at day 3. To better assess the
genotoxicity of the compounds, fewer cells (2,000) were used
to start and a longer observation (7 days) was performed. Cell
proliferation  was  assessed  by  using  the  MTS  assay  as
described above.
Collagen  matrix  contraction  study:  Collagen  gels  were
prepared as described by Shawn et al. [23] using collagen type
I (BD Biosciences, San Jose, CA) and DMEM/F12 (Gibco,
Invitrogen) at a final concentration of 2.0 mg/ml. Freshly
prepared collagen solution (500 μl) was added into each well
of a 24-well plate and incubated at 37 °C in 5% CO2 for 1 h.
A 500 µl suspension containing 1×105 ARPE19 cells were
added to the collagen matrix. RPE cells were used because the
retinal pigment epithelium is the major participating cell in
PVR formation [2,23,24]. An overnight incubation allowed
for the RPE cells to adhere to the collagen gel, after which
500 μl of the test drug solutions were added and incubated for
either 5 min or 50 min. Each drug concentration was tested in
triplicate. For HDP-PMEG 20 μM, 6.32 μM, and 2 μM were
tested and concentrations of 2 mM, 200 μM, and 20 μM for
5-FU. The medium, DMEM/F12, was used as the control.
Four  days  after  drug  exposure,  the  collagen  gel  was
photographed using a digital camera and the gel sizes were
quantified  using  Image-Pro  Plus  6.0  software.  Each  drug
concentration was tested in triplicate and each experiment was
repeated three times.
Statistical  analysis:  One-way  ANOVA  was  used  for  the
analysis of all results. Multiple comparisons among various
concentrations  and  controls  were  made  and  the  observed
significance  levels  were  adjusted  using  the  Bonferroni  or
Dunnett methods. A p value smaller than 0.05 was considered
to  be  statistically  significant.  All  statistical  analysis  was
performed using SAS software (SAS version 9.2, Cary, NC).
RESULTS
Antiproliferation potency: HDP-PMEG inhibited 40% RPE
cell growth at 1 µM while 5-FU achieved similar inhibition at
8 µM. At 1 µM HDP-PMEG had similar inhibitory strength
to daunorubicin. For Müller cells, the inhibitory strength of
HDP-PMEG  was  stronger  than  5-FU  at  all  tested
concentrations and its strength came in between 5-FU and
daunorubicin. For the endothelium-like cell line EA-HY926,
HDP-PMEG demonstrated a similar inhibitory strength to
daunorubicin and was much stronger than 5-FU (Figure 2).
For M23 and SP6.5 cells, HDP-PMEG demonstrated a similar
inhibitory  effect  to  5-FU,  while  HDP-PMEG  had  a
consistently stronger inhibitory effect than 5-FU on OCM1
cells. Daunorubicin had the strongest inhibitory effect on all
three melanoma cell lines (Figure 3). Table 1 summarizes the
characteristics  of  the  four  compounds  using  the  IC50  (the
concentration  needed  to  inhibit  the  50%  of  the  cell
proliferation), the minimum effective concentration, which
was  the  lowest  concentration  showing  significant
proliferation inhibition as compared to the control, and the
mean MTS readings at 1 µM which was in the mid-range of
the tested concentrations.
Cytotoxicity  evaluation:  Figure  4A  demonstrates  the  drug
cytotoxicity results from the trypan blue dye exclusion assay.
All three drugs showed a higher mean percentage of trypan
blue  positive  cells  as  compared  to  the  controls  even  at  a
0.001 µM concentration (5-FU: 8.8% versus 7.6%, p=0.0353;
DNR:  14.6%  versus  7.6%,  p<0.0001;  HDP-PMEG:  10%
versus 7.6%, p=0.0176 Adjusted for multiple comparisons
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Bottom panel: proliferation on EA-HY926 endothelium cell.
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630Figure 3. MTS cell proliferation assay to demonstrate the inhibitory effect on proliferation of the three melanoma cell lines: M23 cell (Upper
panel), OCM1 cell (Center panel), and SP6.5 cell (Bottom panel). For M23 and SP6.5 cells, HDP-PMEG demonstrated a similar inhibitory
effect to 5-FU while HDP-PMEG had a consistent stronger inhibitory effect than 5-FU on the OCM1 cell. Daunorubicin had the strongest
inhibitory effect on all the three cell lines.
Molecular Vision 2011; 17:627-637 <http://www.molvis.org/molvis/v17/a72> © 2011 Molecular Vision
631with Dunnett). The TC50 (the concentration to cause 50% cell
death) for HDP-PMEG and 5-FU was not reached in this study
and for DNR was 3 µM; however, the TC20 was available from
the study and it was 11 µM for HDP-PMEG, 100 µM for 5-
FU, and 0.1 µM for DNR (Figure 4B). To estimate the ocular
therapeutic index (TI=TC50/IC50) which is defined as the ratio
of drug efficacy to the magnitude of its adverse side effects,
we used TC20 and IC20 to calculate the TI. TI was 17.2 for 5-
FU, 1,100 for HDP-PMEG, and 1.25 for DNR. A high ocular
TI will suggest that the compound might prevent proliferation
of cells in vivo without affecting non-dividing cells such as
those of the retina.
Antiproliferation effect from the short contact: Drug exposure
at both 5 min and 50 min caused significant proliferative
inhibition for both 5-FU and HDP-PMEG (Figure 5A-C) on
all three tested cell lines. As a whole, the inhibition was
significantly more with the 50 min contact (p<0.0001). A 50-
min exposure to 2 µM HDP-PMEG induced a 50% inhibition
of ARPE19 cells during a 7-day observation. In the same
study, a 200 µM 5-FU 50-min exposure achieved a similar
percentage  of  proliferation  inhibition.  The  proliferative
inhibition was dose-dependent for HDP-PMEG, while for 5-
FU, doses higher than 200 µM caused a similar degree of
proliferation  inhibition  (25%  of  the  control).  For  anterior
scleral  fibroblasts,  a  20  µM  HDP-PMEG  5-min  exposure
induced a 65% inhibition while even a 20 mM 5-FU did not
achieve the similar magnitude growth inhibition (p<0.0001,
Figure 5C).
Collagen  matrix  contraction  study:  The  collagen  matrix
contraction  study  showed  a  dose-dependent  inhibition  of
collagen matrix contraction for both HDP-PMEG and 5-FU
(Table 2). For both HDP-PMEG and 5-FU, a 50-min exposure
led to a more significant inhibition than that from the 5-min
exposure  (p<0.0001).  For  HDP-PMEG,  6.32  and  20  µM
significantly inhibited the collagen matrix contraction and
their effects are equivalent to 200 and 2000 µM of 5-FU,
respectively  (Table  2).  Two  micromolar  HDP-PMEG  and
20 µM 5-FU did not show significant inhibition of collagen
matrix contraction.
DISCUSSION
The current study demonstrated that HDP-PMEG possesses a
potent antiproliferative property. At present, PVR is still being
treated  by  surgical  procedures  and  pharmacological
prevention or early treatment needs to be further explored. 5-
FU was the first FDA approved small molecule antimetabolite
interfering with DNA and RNA synthesis. Blumenkranz et al.
demonstrated effectiveness of 5-FU in in vivo experimental
TABLE 1. ANTIPROLIFERATIVE COMPOUNDS AND POTENCY PROFILE.
Compound Cell line Minimum effective
concentration tested (μM)
IC50 (μM) Mean OD value of MTS
reading at 1 μM
p value*
PMEG ARPE-19 10 >50 1.01 0.0002
5-FU ARPE-19 10 20 1.05 <0.001
DNR ARPE-19 1 5 0.7 0.99
HDP-PMEG ARPE-19 0.1 10 0.7 ²
PMEG EA-HY926 10 50 1.6 <0.001
5-FU EA-HY926 10 10 1.5 <0.001
DNR EA-HY926 0.001 0.3 0.21 0.13
HDP-PMEG EA-HY926 0.01 0.05 0.36                                    —
PMEG MIO-M1 1 >50 0.98 0.82
5-FU MIO-M1 10 >100 1.54 <0.001
DNR MIO-M1 0.1 0.1 0.5 0.0142
HDP-PMEG MIO-M1 0.01 10 0.9                                     —
PMEG M23 0.1 50 1.51 0.0029
5-FU M23 0.1 3 1.18 0.57
DNR M23 1 2 1.38 0.0301
HDP-PMEG M23 0.1 3 1.04                                    —
PMEG OCM1 10 50 2.26 <0.001
5-FU OCM1 1 20 1.81 0.012
DNR OCM1 0.1 1 0.93 0.064
HDP-PMEG OCM1 0.01 3 1.32                                     —
PMEG SP6.5 1 50 1.65 0.93
5-FU SP6.5 1 10 1.55 0.99
DNR SP6.5 1 2 1.06 0.0682
HDP-PMEG SP6.5 1 5 1.56                                     — 
         IC50: drug concentration needed to inhibit cell proliferation by 50%. Minimum effective concentration: minimum concentration
         tested showing inhibitory action compared with the control. *: p Value derived from comparing the mean OD values at 1 μM
         on the same cell line using HDP_PMEG as control (Dunnett method).
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632models of PVR [25]. However, the recent clinical trials using
5-FU as a perioperative infusion for the management of PVR
did not show significant therapeutic benefit [5,26,27]. Those
clinical studies used 200 µg/ml of 5-FU for perioperative
infusion [5,26,27]. In the current study, we used 260 µg/ml
(2,000 µM) of 5-FU which demonstrated efficacy in both the
antiproliferation assay and the collagen matrix contraction
assay.  The  equivalent  antiproliferative  strength  seen  with
2,000 µM of 5-FU was achieved by using 20 µM of HDP-
PMEG in the collagen contraction study. The antiproliferation
assay revealed that the ocular therapeutic index for HDP-
PMEG was 64 times better than 5-FU, which indicates a better
efficacy and safety profile for HDP-PMEG. The current study
also demonstrated better inhibitory potency of HDP-PMEG
than  5-FU  on  blood  vessel  endothelium  (EA-HY926)
proliferation,  which  is  a  key  process  for  many  types  of
pathological proliferation. Along with HDP-PMEG and 5-FU,
daunorubicin was also tested in the current study. Our study
indicated that daunorubicin had a very narrow therapeutic
window (ocular therapeutic index of 1.25) which was also
reported  by  the  other  investigators  [28,29].  Although
perioperative  daunorubicin  perfusion  with  vitrectomy  had
Figure 4. Cytotoxicity assay on Müller
cell. A: The percentage of trypan blue
positive  cells  (y-axis)  was  plotted
against  the  concentration  of  the  test
compounds  used  (x-axis).  The
concentration unit was micro molar and
the  open  box  represented  a  95%
confidence limit. 5-FU at 100 µM that
was  the  highest  concentration  tested,
caused 20% death of the cell culture,
which was equivalent to HDP-PMEG at
11 µM or DNR at 0.1 µM. B: Exemplary
images from the Müller cell cytotoxicity
study: the upper left panel showing a
counting field from the control in which
31 cells were stained by trypan blue out
of a total of 435 cells, yielding a 7%
trypan blue positive rate. The rest of the
three fields had a trypan blue positive
rate of 19% (38/198) for 10 µM HDP-
PMEG, 18% (46/251) for 100 µM 5-FU,
and  18%  (49/274)  for  0.1  µM
daunorubicin (DNR).
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633shown marginal efficacy in a clinical study [4], therapeutic
effect of a simple ocular application without a delivery system
may be very limited. In contrast, HDP-PMEG had a high
ocular  therapeutic  index  and  was  rationally  designed  for
intravitreal long lasting and slow release. HDP-PMEG may
be  a  better  therapeutic  than  5-FU  and  daunorubicin  for
intraocular  application  to  manage  unwanted  ocular
proliferation. HDP-PMEG, like 5-FU, is a metabolite which
Figure 5. The ARPE19 cell proliferation
inhibitory effect from single short-term
exposure of HDP-PMEG and 5-FU. A:
Following a 50-min contact, 2 µM and
6.32  µM  HDP-PMEG  inhibited  cell
proliferation  by  50%  and  75%,
respectively, which were equivalent to
200 µM and 2,000 µM of 5-FU. The 5-
min exposure also induced significant
proliferation  inhibition.  However,  the
inhibition was consistently less than that
from  50-min  exposure  cross  all
concentrations. The mark on the top of
each  bar  represents  the  standard
deviation.  B:  The  Müller  cell
proliferation  inhibitory  effect  from  a
single  short-term  exposure  of  HDP-
PMEG and 5-FU. Both 5- and 50-min
exposure  induced  dose  dependent
inhibition by 5-FU and HDP-PMEG. In
a 50-min exposure, 2 µM HDP-PMEG
induced a similar growth inhibition as
that observed by 200 µM 5-FU. C: The
anterior scleral fibroblast proliferation
inhibitory  effect  from  a  single  short-
term exposure of HDP-PMEG and 5-
FU. For the anterior scleral fibroblasts,
a 20 µM HDP-PMEG 5-min exposure
induced a 65% inhibition while even 20
mM 5-FU did not achieve the similar
magnitude growth inhibition.
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634interferes with DNA synthesis and cell proliferation. It is not
surprising that all three tested compounds caused a certain
degree of cytotoxicity in the Müller cell line, even at a low
concentration,  because  the  tested  cells  were  perpetually
proliferating cells. In an in vivo situation, most retinal cells
are quiescent cells with minimal replication. Studies have
shown that a 1 mg 5-FU intravitreal injection into rabbit eye
(5 mM) caused no significant inhibition of protein synthesis
in photoreceptor cells and ganglion cells [30]. In a human
study, a 200 µg/ml (1.53 mM) infusion during a vitrectomy
seemed to be safe [5,31]. The safety and toxicity of HDP-
PMEG for intraocular use needs to be investigated in vivo
studies.
It has been suggested that the genotoxicity of PMEG is
comparable to that of mitomycin C [9] which is used more
often than 5-FU as an adjuvant for glaucoma filtering surgery
[32]. The current study showed that HDP-PMEG possesses a
similar genotoxicity to 5-FU. The benefit of an effective short-
term treatment such as intraocular infusion during vitrectomy
is  clear.  In  this  way,  a  drug  may  be  given  as  a  single
intraoperative dose and washed away following the treatment
period,  thus  controlling  the  therapeutic  exposure  more
precisely.
In the current study, we also investigated HDP-PMEG on
three melanoma cell lines and the results were encouraging.
HDP-PMEG demonstrated an equivalent cell proliferation-
arresting effect on SP6.5 and M23 cell lines to 5-FU and
improved  potency  on  OCM1  cells.  HDP-PMEG  is  a
hydrophobic crystalline compound and becomes a suspension
in  water-based  solutions.  The  suspension  may  be  directly
injected into the tumor mass without being quickly distributed
systemically to cause systemic side effects.
In summary, the current study evaluated HDP-PMEG in
vitro for its antiproliferative potency and cytotoxicity while
both  5-FU  and  daunorubicin  were  used  as  a  comparison.
Ocular cell lines were used throughout the study. Cell lines
have been extensively used in vitro for drug screening to
determine the inhibitory growth activity of drugs [33]. Usage
of well developed cell lines facilitates the comparison among
compounds  and  studies.  We  acknowledge  that  primary
cultured cells may differ from cell lines. However, recently,
two  studies  demonstrated  that  primary  cultured  RPE  and
ARPE19 responded similarly to the tested toxicants [34,35].
This may be due to the similar gene expression related to
apoptosis [36], through which drug or toxicants exert their
growth  inhibition  or  cytotoxicity.  The  in  vitro  data  are
encouraging and suggests that HDP-PMEG may be useful in
managing unwanted ocular proliferation such as various PVR
and retinal surface proliferation. However, its efficacy and
safety need to be studied further in small experimental animal
models.
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